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INTRODUCTION
Hypertension (HTN) is the one of the cardiovascular 
diseases estimated to cause 7.1 million deaths annually, 
accounting for 13% of all deaths globally. Overall 26.4% 
(972 million) of the adult world population was estimated 
to have HTN in the year 2000. This is projected to increase 
by 29.2% (1.56 billion) for the year 2025.
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AbSTRACT
Hypertension is the very common chronic disease in rural, urban and semi-urban areas of today’s world, which 
needs continuous monitoring and treatment through out the life. Lack of education, lifestyle modification, 
and low level of understanding on disease management in rural people will influence directly on their 
quality of life (QOL). The objective of this study was to know the impact of clinical pharmacist interventions 
on medication adherence and QOL. It was a prospective, randomized and interventional study. Fifty-six 
patients were enrolled; only 52 patients completed the study. Interventional group patients received patient 
counselling, patient information leaflets (PILS), and frequent telephonic reminding. In the baseline, first and 
second follow-ups, medication adherence and QOL were assessed by using Morisky Medication Adherence 
Scale (MMAS) and Medication Adherence Report Scale (MARS) Questionnaires and SF-12v2 Quality of life 
Questionnaire in both the groups. The results showed that systolic blood pressure P value in the second 
follow-up was 0.086+ when compared to baseline follow-up P value 0.094. The diastolic blood pressure 
reading of the intervention group at the second follow-up was 77.73 ± 3.63 in mmHg when compared to 
the baseline, i.e. 86.62 ± 11.35 in mmHg. The MMAS and MARS scores P values were 0.007**, 1.000, 
<0.001**; 0.007, 0.014 and 0.000 at the baseline, first and second follow-ups, respectively. The QOL score 
P values of physical component scale and mental component scale showed highly significant. This study 
concluded/showed that the impact of clinical pharmacist provided patient counselling had a positive impact 
on medication adherence and QOL.
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In India, the prevalence of HTN reports was increasing 
rapidly in the urban, i.e. 25% of adults, and gradually 
even in rural areas, i.e. 10% of individuals are affected. 
The same study estimated that there were about 
66 million hypertensive patients in India (out of 66 million 
hypertensive patients—34 million are in urban areas 
and 32 million in rural areas). This clearly indicates that 
medication nonadherence is the multifaceted problem, 
responsible for increasing the important medical and public 
health issues like worsened therapeutic outcome, higher 
hospitalization rates, and increased health care costs.[1]
According to WHO Medication Adherence is defined 
as “the extent to which a person’s behaviour [in] taking 
medication corresponds with agreed recommendations 
from a health care provider” (World Health Organization, 
2003).[2] Therefore, medication adherence is one of the 
important factors helps in keeping the vital link between the 
treatment and the therapeutic outcomes in medical care.[3]
The two methods available for measuring adherence 
are direct and indirect methods. In direct methods 
measurement of concentrations of a drug or its metabolite 
in blood or urine, and detection or measurement in blood 
of a biologic marker added to the drug formulation are 
used. These approaches are expensive, burdensome to 
the health care provider, and susceptible to distortion by 
the patient. The indirect methods include asking the patient 
about how easy it is for him or her to take prescribed 
medication, assessing clinical response, performing 
pill counts, ascertaining rates of refilling prescriptions, 
collecting patient questionnaires, using electronic 
medication monitors, measuring physiologic markers, 
asking the patient to keep a medication diary, and assessing 
children’s adherence by asking the help of a caregiver, 
school nurse, or teacher. These questioning the patient 
methods will help the healthcare provider for estimating 
the medication adherence indirectly without pain.[4]
Quality of life (QOL), a broad multidimensional concept, 
usually includes subjective evaluations of both positive and 
negative aspects of life. Health is one of the important 
domains of overall QOL; health related quality of life 
(HRQOL) questions about perceived physical and mental 
health and function have become an important component 
of health surveillance and are generally considered as valid 
indicators of service needs and intervention outcomes.[5-11]
This study was carried out in a 750 bedded tertiary care 
rural hospital of General Medicine Department, for 
the first time to know the impact of clinical pharmacist 
interventions on medication adherence and QOL.
MATERIALS AND METHODS
This was a prospective randomized and interventional study 
conducted in the Medicine department of Adichunchanagiri 
Hospital and Research Center, B G Nagara, for a period 
of 7 months. Ethical committee clearance was obtained 
prior to the study from Adichunchanagiri Hospital and 
Research Centre.
Study criteria
Inclusion criteria
•	 Inpatients and outpatients of General Medicine 
Department who were diagnosed and on medication 
for hypertension over a period of 6 months.
•	 18 years and above patients of either sex.
•	 Patients who are willing to participate and give the 
consent form.
Exclusion criteria
•	 Patients with comorbidities (more than four diseases).
•	 Pregnant/lactating women.
Sources of data
Inpatients
Patient case records, medication charts and lab reports.
Outpatients
Prescriptions.
Materials used
Informed consent form, patient data collection form, 
patient information leaflets (PILS) regarding disease and 
drugs, diary card, questionnaires [Morisky Medication 
Adherence Scale (MMAS), Medication Adherence Report 
Scale (MARS), SF-12v2 Quality of Life (QOL) Scale, and 
patient satisfaction questionnaire (PSQ)].
Study procedure
After obtaining the patient consent, the patients were 
randomized into the intervention and control group by a 
simple randomization technique [i.e. odd (in the control 
group) and even numbers (in an interventional group)] in 
order to minimise/prevent the bias. The required details/data 
were obtained from outpatient cards (OP card), case records 
of inpatients, and by direct interviews. The patients were also 
informed to come for the first and second follow‑ups after 
1 month from the base line or from the date of enrolment.
The control and intervention group patients were 
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recorded in the patient data collection forms along with 
baseline blood pressure levels and body mass index (BMI). 
In order to know the medication adherence behaviour 
(MAB) of both control and intervention groups, they were 
provided with the dairy card and which was collected at 
the end of the study. The control group did not provide 
with any counselling and PILS (patient information leaf 
lets) at the baseline and in the first follow‑up. However, 
they were provided with oral instruction and PIL at the 
end of the second follow-up. The intervention group 
patients were counselled on various aspects such as, drugs, 
lifestyle changes, and their disease management, and told 
them to inform if any unwanted and unintended effects of 
drugs occurs at any follow-ups. These patients mediation 
adherence and QOL were assessed by using standard 
questionnaires, i.e. morisky medication adherence scale 
(4 items), MARS (5 items), and SF-12v2 QOL to know 
their medication adherence and QOL, respectively, in the 
baseline and follow-ups. The answers given by them were 
recorded. In each follow-ups and baseline the patient’s 
blood pressure values were noted/measured. At the end 
of the second follow-up, diary cards were collected back.
The patient satisfaction questionnaire (PSQ) was prepared 
by selecting the suitable questions from the validated 
osteoporosis patient satisfaction questionnaire (OPSQ) 
and the expert’s opinion was taken to administer for 
the intervention group, to know the impact of clinical 
pharmacy services and types of counselling services 
provided by the clinical pharmacist. The obtained data 
were subjected for statistical analysis.
Statistical methods
Descriptive statistical analysis has been carried out in this 
study. Results on continuous and categorical measurements 
are presented on mean±SD (min–max) and in number (%). 
Significance is assessed at the 5% level of significance.[12-15]
RESULTS
A total of 118 patients were approached and explained 
about the study and study procedure briefly, out of which 
only 56 patients agreed to participate in the study. Four 
patients were dropped out because of negligence, left the 
place, illiteracy, and age factor. The total number of patients 
who had completed the study was 52 (26C+26I).
The basic demographic variables of patients showed, at 
the age group of 51–60 (34.6%), 61–70 (38.5%) years was 
found to be more in the control and in the intervention 
group. In gender wise, males were more, 16 (61.5%) and 
21 (80.8%), than the females, 10 (38.5%) and 5(19.2%), 
in both the interventional and control group. The BMI 
results showed normal range patients were more in both 
the groups. Education, occupation, and annual income 
details showed more illiterates, farmers, Rs. <25,000 in 
both the groups, respectively. The clinical variable of 
patients showed that only 14 (53.8%) had alcohol habit 
in the control group and non-alcoholics were found to be 
14 (53.8%) in the intervention group. Nonsmokers were 
found more in both the groups. The diabetes mellitus was 
the one of the more common comorbid conditions and 
there is no suggestive of family history of disease in both 
the groups [Tables 1 and 2].
The distribution of systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) of the patients, at the 
base line and second follow-ups, i.e., SBP (in mmHg) 
of control and intervention groups was 138.85 ± 16.03, 
147.54 ± 20.45 and 131.08 ± 5.16, 128.27 ± 6.35, 
respectively. The DBP (in mmHg) of the control and 
Table 1: Patients demographic details
Variables Control group Intervention group
N % N %
Age in years
20–30 – – – –
31–40 3 11.5 0 0.0
41–50 3 11.5 8 30.8
51–60 9 34.6 7 26.9
61–70 7 26.9 10 38.5
>70 4 15.4 1 3.8
Gender
Male 21 80.8 16 61.5
Female 5 19.2 10 38.5
BMI (kg/m2)
<18.5 3 11.5 4 15.4
18.5–25.0 19 73.1 13 50.0
25.0–30.0 4 15.4 8 30.8
>30.0 0 0.0 1 3.8
Education
Illiterate 16 61.5 18 69.2
Primary 3 11.5 6 23.1
High school 3 11.5 1 3.8
Pre-university 1 3.8 0 0.0
Degree+ 3 11.5 1 3.8
Occupation
Farmer 15 57.7 11 42.3
House wife 4 15.4 8 30.8
Employed 5 19.2 2 7.7
Business 1 3.8 4 15.4
Retired income (Rs)
<25000 12 46.2 17 65.4
25001–50000 9 34.6 8 30.8
5001–1,00,000 1 3.8 0 0.0
1–1.5 lakh 1 3.8 1 3.8
>1.5 lakh 3 11.5 0 0.0
Total 26 100.0 26 100.098   Journal of Young Pharmacists Vol 4 / No 2
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intervention groups at the base line and second follow-ups 
was 81.12 ± 7.16, 86.62 ± 11.35 and 78.46 ± 4.12, 
77.73 ± 3.63, respectively [Table 3].
The distribution of medication adherence scores of 
MMAS and MARS statistically showed a strongly 
significant P value, in both the baseline and second 
follow-up, i.e. 0.007** and <0.001** for MMAS and 
for MARS the P values are 0.000, 0.082, 0.003, 0.164, 
and 0.000 from questions 1–5 at the second follow-up. 
The overall total of MARS score P value at the second 
follow-up was 0.000 [Tables 4 and 5].
The comparative distribution of individual QOL domain scores 
(i.e. PF, RP, BP, GH, VT, SF, RE, and MH) of patients at the 
base line and second follow-up results was 0.006**, 0.012**, 
<0.001**, 0.054+, 0.193, 0.11*, <0.001**, 0.039* and 0.005**, 
<0.001**, <0.001**, 0.008**, <0.001**, <0.001**, <0.001**, 
<0.001**, showing highly significant values [Table 6].
The distribution of over all QOL, i.e. physical component 
scale (PCS) and mental component scale (MCS) scores in two 
groups of patients showed at the baseline, first and second 
follow-ups were (0.003**, 0.153, <0.001**) and (0.006**, 
0.394, <0.001**), respectively, this shows a good improvement 
in both the component/over all [Table 7].
The patient satisfaction about the pharmacist involvement 
in the disease management showed the average score of 
33.73 ± 4.3 (max score 45) for the clinical pharmacy services 
and 18.38 ± 1.88 (max score 25) for types of counselling 
Table 2: Clinical variables of hypertensive patients
Clinical variables Control group Intervention group
N % N %
Alcohol
No 12 46.2 14 53.8
Yes 14 53.8 12 46.2
Smoking
No 15 57.7 16 61.5
Yes 11 42.3 10 38.5
Co-morbid conditions
Acute MI 0 0.0 1 3.8
Anemia 1 3.8 1 3.8
Asthma 3 11.5 1 3.8
CCF 1 3.8 0 0.0
CKD 0 0.0 2 7.7
COPD 1 3.8 0 0.0
DM 9 34.6 10 38.5
HTN 0 0.0 0 0.0
IHD 2 7.7 3 11.5
UTI 0 0.0 1 3.8
Others 1 3.8 1 3.8
Family history of disease
No 19 73.1 16 61.5
Yes 7 26.9 10 38.5
Total 26 100.0 26 100.0
CCF- Congestive cardiac failure, CKD- Chronic kidney disease, COPD- Chronic 
obstructive pulmonary disease, DM- Diabetes millets, HTN- Hypertension,  
IHD – Ischemic heart disease, UTI- Urinary tract infection
Table 3: Comparative distribution of blood pressure of 
hypertensive patients
Blood pressure Control group Intervention group P value
SBP (mmHg)
Baseline 138.85 ± 16.03 147.54 ± 20.45 0.094
First follow-up 131.58 ± 8.56 134.92 ± 8.16 0.155
Second follow-up 131.08 ± 5.16 128.27 ± 6.35 0.086+
DBP (mmHg)
Baseline 81.12 ± 7.16 86.62 ± 11.35 0.042*
First follow-up 79.38 ± 4.54 80.77 ± 5.25 0.314
Second follow-up 78.46 ± 4.12 77.73 ± 3.63 0.500
*Statistically moderately significant, SBP-systolic blood pressure,  
DBP-diastolic blood pressure
Table 4: Comparison of Morisky medication adherence 
scale scores
MMAS Control group Intervention group P value
Baseline 2.73 ± 0.72 2.08 ± 0.93 0.007**
First follow-up 3.00 ± 0.63 3.00 ± 0.57 1.000
Second follow-up 3.12 ± 0.71 3.92 ± 0.27 <0.001**
MMAS: Morisky medication adherence scale, **Statistically strongly  significant
Table 5: Comparison of medication adherence reporting 
scale scores
MARS Control group Intervention group P value
1Q. I forget to take 
the medicine
Baseline 3.65 ± 1.23 3.08 ± 1.16 0.089
First follow-up 3.65 ± 1.16 4.27 ± 0.87 0.036
Second follow-up 3.88 ± 1.14 4.96 ± 0.20 0.000
2Q. I alter the dose 
of medicine
Baseline 4.88 ± 0.59 4.77 ± 0.82 0.561
first follow-up 4.81 ± 0.69 4.92 ± 0.39 0.464
Second follow-up 4.69 ± 0.88 5.00 ± 0.00 0.082
3Q. I stop taking 
medicine for a while
Baseline 3.73 ± 1.34 3.15 ± 1.26 0.116
First follow-up 4.12 ± 1.21 4.38 ± 0.85 0.358
Second follow-up 4.42 ± 0.95 5.00 ± 0.00 0.003
4Q. I decided to 
miss out a dose
Baseline 4.92 ± 0.39 4.65 ± 0.8 0.129
First follow-up 4.88 ± 0.59 5.00 ± 0.00 0.322
Second follow-up 4.81 ± 0.69 5.00 ± 0.00 0.164
5Q. I take less than 
instructed
Baseline 4.92 ± 0.39 4.85 ± 0.61 0.592
First follow-up 5.00 ± 0.00 5.00 ± 0.00 0.000
Second follow-up 5.00 ± 0.00 5.00 ± 0.00 0.000
Total
Baseline 22.12 ± 2.01 20.5 ± 2.16 0.007
First follow-up 22.46 ± 1.96 23.58 ± 1.06 0.014
Second follow-up 22.81 ± 2.38 24.96 ± 0.20 0.000
MARS: Medication Adherence Report ScaleJournal of Young Pharmacists Vol 4 / No 2  99
Ramanath, et al.: Clinical pharmacist impact in MAB and QOL in HTN patients
[Table 8]. The dairy cards were returned by only 29 patients 
(11 control and 18 intervention) at the end of the follow-up.
DISCUSSION
In this study, only 56 patients were accepted and 
involved/participated because maximum people had an 
afraidness to give the consent, location and difficulty in 
follow-ups and what the pharmacist can do. The consented 
people were participated and only four were dropped 
out, due to inability to come for regular follow-up, due to 
negligence, age factor, illiteracy, and left the place.
The results of the blood pressure (both SBP and 
DBP values) show a very good improvement from the base 
line to the second follow-up. This strongly showed that there 
is a clinical pharmacist influence/positive impact on patient 
counselling (i.e., interventions made and provided PILs).
The assessment of medication adherence scores by MMAS 
clearly showed that there was a good improvement in MAB 
of the patients both in control and intervention groups. 
The control group, showed little improvement because of 
repeated follow-ups that made them to think about life 
maintenance. However there was a very good improvement 
in intervention when compared to the control group 
because the intervention group patients were provided with 
counselling, PILS, and frequent telephone reminding makes 
them to strongly adapt to think about disease management.
Table 6: Comparative distribution of quality of life 
(SF-12v2 QOL) domain scores in HTN patients
QOL Control 
group
Intervention 
group
P value
Physical functioning
Baseline 50.00 ± 23.45 27.88 ± 31.09 0.006**
First follow-up 54.81 ± 28.30 38.46 ± 28.49 0.043*
Second follow-up 53.85 ± 29.74 74.04 ± 19.34 0.005**
Role-Physical
Baseline 47.60 ± 12.76 36.06 ± 18.48 0.012**
First follow-up 46.63 ± 12.53 44.71 ± 15.48 0.625
Second follow-up 45.67 ± 12.72 71.15 ± 15.72 <0.001**
Bodily Pain
Baseline 48.08 ± 14.01 27.88 ± 17.79 <0.001**
First follow-up 49.04 ± 13.19 46.15 ± 13.59 0.441
Second follow-up 48.08 ± 12.09 69.23 ± 10.74 <0.001**
General Health
Baseline 48.85 ± 18.35 36.73 ± 25.37 0.054+
First follow-up 53.85 ± 17.45 52.69 ± 21.22 0.831
Second follow-up 60.19 ± 13.15 70.77 ± 14.40 0.008**
Vitality
Baseline 56.73 ± 11.31 50.00 ± 23.45 0.193
First follow-up 59.62 ± 12.40 50.96 ± 19.34 0.061+
Second follow-up 50.00 ± 18.71 69.23 ± 14.68 <0.001**
Social functioning
Baseline 50.96 ± 13.19 38.46 ± 20.29 0.011*
First follow-up 51.92 ± 15.69 46.15 ± 18.29 0.228
Second follow-up 53.85 ± 16.87 76.92 ± 14.01 <0.001**
Role-emotional
Baseline 52.88 ± 15.93 33.65 ± 17.60 <0.001**
First follow-up 50.48 ± 13.91 48.08 ± 15.29 0.556
Second follow-up 49.52 ± 15.2 72.12 ± 15.54 <0.001**
Mental health
Baseline 52.88 ± 14.28 44.23 ± 15.10 0.039*
First follow-up 53.85 ± 11.60 50.00 ± 14.14 0.289
Second follow-up 53.85 ± 13.59 69.71 ± 11.82 <0.001**
QOL: Quality of Life; *Statistically moderately significant; ** Statistically strongly  
significant; +Statistically suggestive significance
Table 7: Comparative distribution of quality of life 
(SF-12v2 QOL) PCS and MCS Scores of patients
QOL Control group Intervention group P value
Physical component  
summary
Baseline 39.17 ± 5.97 33.09 ± 7.95 0.003**
First follow-up 40.55 ± 6.67 37.96 ± 6.19 0.153
Second follow-up 40.81 ± 5.60 47.43 ± 5.29 <0.001**
Mental component  
summary
Baseline 41.39 ± 5.58 36.77 ± 5.98 0.006**
First follow-up 41.13 ± 4.74 39.80 ± 6.25 0.394
Second follow-up 40.35 ± 4.98 49.19 ± 4.08 <0.001**
**Statistically strongly  significant, PCS-Physical component summary,  
MCS-Mental component summary
Table 8: Patient satisfaction questionnaire about the 
pharmacist provided clinical pharmacy services and 
types of counselling
PSQ Hypertension
Questions on clinical pharmacy services
Q1. How would you rate your understanding of 
hypertension since your participation in this study?
3.85 ± 0.61
Q2. Were the follow-up session with the pharmacist 
kept on time?
3.35 ± 1.09
Q3. During the appointment, was there adequate time to 
discuss your problem with the pharmacist?
3.38 ± 0.90
Q4. If you have questions about your HTN medicines, 
would you trust an answer from the pharmacist?
3.85 ± 0.61
Q5. Since your participation in this study, how would 
you rate your understanding of your HTN medication?
4.00 ± 0.49
Q6. Since your participation in this study, do you have 
more or less problems when it comes to taking your 
HTN medications?
3.54 ± 0.65
Q7. How useful was the service provided by the 
pharmacist in this study?
4.12 ± 0.43
Q8. Has the advice given by the pharmacist affected 
your life in general?
3.62 ± 0.70
Q9. Do you agree that the pharmacist should continue 
his services in the clinic to help patients with their 
chronic disease medications?
4.04 ± 0.45
Total 33.73 ± 4.3
Questions on types of counselling 
Q10. Explanation of HTN 4.12 ± 0.33
Q11. Explanation on the purpose of the medicine(s) 3.38 ± 0.75
Q12. Advice on how best to take medicine(s) 3.08 ± 0.56
Q13. Explanation on possible side effects 3.77 ± 0.51
Q14. Disease/drug pills and diary card  4.04 ± 0.45
Total 18.38 ± 1.88100   Journal of Young Pharmacists Vol 4 / No 2
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Medication adherence report scale
The comparative results of the baseline to the second 
follow-up shows that there is a good improvement in 
medication adherence and the various factors influencing 
for the nonadherence rate was reduced from the baseline 
to the second follow-up. This point strongly suggests that 
the pharmacist influence had a very important role in the 
MAB. The MAB directly influences positively on QOL of 
a chronic patient
The various QOL domains scores showed a good 
improvement when compared the baseline to first 
follow‑up and from first follow‑up to second follow‑up, 
and the baseline to second follow‑up. The final individual 
domains suggest that the overall QOL was improved. 
This strongly suggests a positive influence on their QOL. 
However, still there is a need of continuous monitoring to 
manage their disease/QOL in a constant manner.
The stress is the one of the factor which will influence on 
the QOL (i.e. physical and mental health). Comparison of 
QOL PCS and MCS scores of patients after intervention 
demonstrated a larger improvement in PCS and MCS than 
control. The mental strength/stamina is the one which 
is directly proportional to the physical activity so more 
improvement in the MCS clearly states that there was an 
improvement in the management of their disease. Even the 
control group patients stated/felt that there was a need of 
more information on other drugs. The comparison of overall 
QOL domains shows that there are strongly significant values.
The dairy cards were provided to control and interventional 
group patients as a reminder to their medications returned 
back was less. This may be due to forgetfulness, lack of 
education, and negligence. This showed more observation 
on returning of this dairy card will also enhance the disease 
management.
Seventy six percent of the patient satisfied about the 
pharmacist provided clinical pharmacy services and types 
of counselling was observed. This strongly suggest that 
the pharmacist provided clinical pharmacy services and 
the patient counselling had a very good impact and need to 
be find out reasons and strategies to improvise it to 100%.
CONCLUSION
This study showed that clinical pharmacist intervention 
among rural population has a very strong positive impact 
in creating awareness about the disease, and its maintenance 
by increasing their medication adherence and QOL.
This study also concluded that pharmacist involvement/need 
is very important in other chronic disease managements 
of rural population for increasing the QOL by preventing 
recurrence of disease, its progression, and minimizing of 
hospital admissions.
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